These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 18343784)
1. CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. Shi XY; Bhagwandeen B; Leong AS Am J Clin Pathol; 2008 Apr; 129(4):571-7. PubMed ID: 18343784 [TBL] [Abstract][Full Text] [Related]
2. CDX2 and LI-cadherin expression in esophageal mucosa: use of both markers can facilitate the histologic diagnosis of Barrett's esophagus and carcinoma. Weimann A; Zimmermann M; Gross M; Slevogt H; Rieger A; Morawietz L Int J Surg Pathol; 2010 Oct; 18(5):330-7. PubMed ID: 20444732 [TBL] [Abstract][Full Text] [Related]
3. Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis. Xiao ZY; Ru Y; Sun JT; Gao SG; Wang YF; Wang LD; Feng XS Asian Pac J Cancer Prev; 2012; 13(1):247-50. PubMed ID: 22502678 [TBL] [Abstract][Full Text] [Related]
4. Divergent expression of MUC5AC, MUC6, MUC2, CD10, and CDX-2 in dysplasia and intramucosal adenocarcinomas with intestinal and foveolar morphology: is this evidence of distinct gastric and intestinal pathways to carcinogenesis in Barrett Esophagus? Khor TS; Alfaro EE; Ooi EM; Li Y; Srivastava A; Fujita H; Park Y; Kumarasinghe MP; Lauwers GY Am J Surg Pathol; 2012 Mar; 36(3):331-42. PubMed ID: 22261707 [TBL] [Abstract][Full Text] [Related]
5. The diagnosis and management of Barrett's esophagus. DeMeester SR; DeMeester TR Adv Surg; 1999; 33():29-68. PubMed ID: 10572561 [TBL] [Abstract][Full Text] [Related]
6. Does CDX2 expression predict Barrett's metaplasia in oesophageal columnar epithelium without goblet cells? Kerkhof M; Bax DA; Moons LM; van Vuuren AJ; van Dekken H; Steyerberg EW; Kuipers EJ; Kusters JG; Siersema PD; Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1613-21. PubMed ID: 17206949 [TBL] [Abstract][Full Text] [Related]
8. [Mucosal biopsy diagnosis of Barrett's esophageal: an update]. Wang L; Wang LP Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):497-500. PubMed ID: 21055188 [No Abstract] [Full Text] [Related]
9. Abundant expression of the intestinal protein villin in Barrett's metaplasia and esophageal adenocarcinomas. Regalado SP; Nambu Y; Iannettoni MD; Orringer MB; Beer DG Mol Carcinog; 1998 Jul; 22(3):182-9. PubMed ID: 9688144 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry for CDX2 expression in non-goblet-cell Barrett's oesophagus. Behan M; Gledhill A; Hayes S Br J Biomed Sci; 2014; 71(2):86-92. PubMed ID: 24974686 [TBL] [Abstract][Full Text] [Related]
11. Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinoma. Kennedy MT; Jordan RC; Berean KW; Perez-Ordoñez B J Clin Pathol; 2004 Sep; 57(9):932-7. PubMed ID: 15333652 [TBL] [Abstract][Full Text] [Related]
12. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036 [TBL] [Abstract][Full Text] [Related]
13. Foveolar type dysplasia in Barrett esophagus. Brown IS; Whiteman DC; Lauwers GY Mod Pathol; 2010 Jun; 23(6):834-43. PubMed ID: 20228780 [TBL] [Abstract][Full Text] [Related]
14. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction. Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318 [TBL] [Abstract][Full Text] [Related]
15. CDX2 protein expression compared to alcian blue staining in the evaluation of esophageal intestinal metaplasia. Johnson DR; Abdelbaqui M; Tahmasbi M; Mayer Z; Lee HW; Malafa MP; Coppola D World J Gastroenterol; 2015 Mar; 21(9):2770-6. PubMed ID: 25759548 [TBL] [Abstract][Full Text] [Related]
16. Total endoscopic eradication of Barrett's esophagus: study methodology, candidate selection, and clinical outcomes. Shaheen NJ; Spechler SJ Endoscopy; 2008 Dec; 40(12):994-9. PubMed ID: 19065482 [No Abstract] [Full Text] [Related]
17. Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequence. Hayes S; Ahmed S; Clark P J Clin Pathol; 2011 Feb; 64(2):110-3. PubMed ID: 21106545 [TBL] [Abstract][Full Text] [Related]
18. CDX2 expression in columnar metaplasia of the remnant esophagus in patients who underwent esophagectomy. Bax D; Siersema PD; Moons LM; Dekken Hv; Tilanus HW; Kusters JG; Kuipers EJ J Clin Gastroenterol; 2007 Apr; 41(4):375-9. PubMed ID: 17413605 [TBL] [Abstract][Full Text] [Related]
19. Expression of CDX2 and MUC2 in Barrett's mucosa. Steininger H; Pfofe DA; Müller H; Haag-Sunjic G; Fratianu V Pathol Res Pract; 2005; 201(8-9):573-7. PubMed ID: 16259110 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination. Çoban Ş; Örmeci N; Savaş B; Ekiz F; Ensari A; Kuzu I; Palabıyıkoğlu M Dis Esophagus; 2013; 26(2):189-96. PubMed ID: 22591041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]